
the range of from about 0.9 mg/kg to about 2.1 mg/kg of patient body weight per intravenous administration, preferably of from about 1.2 to about 1.8 mg/kg of patient body weight per intravenous administration.

8. The compound or the pharmaceutical composition for use according to claim 7, wherein the dose is about 0.9 mg/kg, about 1.2 mg/kg, about 1.5 mg/kg, about 1.8 mg/kg, or about 2.1 mg/kg of patient body weight, preferably about 1.2 mg/kg of patient body weight.

9. The compound or the pharmaceutical composition for use according to any one of claims 1 to 8, wherein the average DAR for the compound is about 2.8.

10. Use of a therapeutically effective amount of a compound of formula (I)



,

wherein 2.6-2.9 represent an average DAR for the compound in the manufacture of a medicament for treating a trastuzumab emtansine refractory HER2 IHC 3+ or HER2 IHC 2+/FISH positive cancer patient.

11. The use of claim 10, wherein the average DAR for the compound is about 2.8.

12. The use of claim 10 or 11, wherein the patient is refractory to both trastuzumab and trastuzumab emtansine.

13. The use of claim 12, wherein the patient is refractory to all of trastuzumab, lapatinib and trastuzumab emtansine.

14. The use of claim 10 or 11, wherein said cancer patient is a breast cancer patient.